Hot Biotech Movers: VIVUS Inc. (NASDAQ:VVUS), Arena Pharmaceuticals(NASDAQ:ARNA), MannKind Corp. (NASDAQ:MNKD), Galena Biopharma(NASDAQ:GALE), Ariad Pharmaceuticals Inc. (NASDAQ:ARIA)


On 7 October VIVUS, Inc. (NASDAQ:VVUS) was claiming that its Qsymia has the potential to treat obese or overweight patients with type 2 diabetes. The company made the disclosure through its paper that was published online in the Diabetes Care journal. VIVUS Inc. (NASDAQ:VVUS) in last trading activity increased 2.41% to close at $3.40. Company weekly performance is -5.56% while its quarterly performance stands at -29.46%. VIVUS Inc. (NASDAQ:VVUS) is -66.96% away from its 52 week high.

Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) announced that data from the Phase 3 clinical trial program for BELVIQ (lorcaserin HCl) CIV was presented at the American College of Clinical Pharmacy (ACCP) Annual Meeting Oct. 12-15, 2014, in Austin, Texas. On last trading day Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) increased 0.49% to close at $4.10. Its volatility for the week is 4.17% while volatility for the month is 5.26%. ARNA’s sales growth for past 5 years was 52.70% and its EPS growth for past 5 years was 51.20%. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) monthly performance is -0.24%.

MannKind Corp (NASDAQ:MNKD) VP Juergen Martens sold 63,800 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $5.48, for a total transaction of $349,624.00. Following the transaction, the vice president now directly owns 220,883 shares of the company’s stock, valued at approximately $1,210,439. On last trading day MannKind Corp. (NASDAQ:MNKD) increased 4.82% to close at $5.65. Its volatility for the week is 5.74% while volatility for the month is 6.02%. MNKD’s EPS growth for past 5 years was 26.50%. MannKind Corp. (NASDAQ:MNKD) monthly performance is -7.07%.

Galena Biopharma, Inc. (NASDAQ:GALE) on 14 October announced the notice of allowance from the Japanese Patent Office for NeuVax (nelipepimut-S) covering the use of NeuVax alone or in combination with other agents to prevent recurrence of any HER2/neu expressing breast cancer tumor having an immunohistochemistry level of 1+ or 2+, or a fluorescence in situ hybridization (FISH) rating of less than about 2.0. Galena Biopharma, Inc. (NASDAQ:GALE) has 0.50% insider ownership while its institutional ownership stands at 19.30%. In last trading activity company’s stock closed at $1.89.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it will report its third quarter 2014 financial results on Wednesday, November 5, 2014, before the market opens. Following the announcement, at 8:30 a.m. On Thursday shares of Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) closed at $5.71. Company’s sales growth for last 5 years was 45.10% and EPS growth for next 5 years is recorded as 41.40%.


Leave a Reply

Your email address will not be published. Required fields are marked *